{
    "paper_id": "28536c3bbffda431aafeb11e56115a5680e1d928",
    "metadata": {
        "title": "",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Medical patients regularly present with complicated multi-pathologies, often involving more than one system, each having a signifi cant impact on the others. This chapter looks at some of the more common pathologies that the on call physiotherapist will encounter, highlighting important points to consider when assessing and treating the medical patient.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Elizabeth Thomas"
        },
        {
            "text": "COPD exacerbations may be idiopathic or caused by bacterial or viral infection. Hypoxaemia will be the primary reason for the call out and the aim of physiotherapy is to establish the cause of hypoxaemia and treat as appropriate.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "COPD"
        },
        {
            "text": "Major causes of hypoxaemia in COPD exacerbation include: \u2022 Bronchospasm \u2022 Sputum retention \u2022 Consolidation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "COPD"
        },
        {
            "text": "Others common causes include: \u2022 Cardiac event \u2022 Pneumothorax \u2022 Pulmonary embolus.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "COPD"
        },
        {
            "text": "Oxygen is a drug and should be prescribed. Prescription should include percentage, fl ow rate, delivery device and whether oxygen delivery is intermittent or continuous. Any changes to oxygen therapy should be discussed with medical staff. Prescription may be fl exible, for example 'maintain sats between 88% and 92%', in which case the FiO 2 can be changed as necessary until the desired saturation is reached.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "CONTROLLED OXYGEN THERAPY AND COPD"
        },
        {
            "text": "NB: Liaise with medical staff to establish target SpO 2 levels for each individual patient. They may be as low as 80-85% in chronically hypoxic patients.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "CONTROLLED OXYGEN THERAPY AND COPD"
        },
        {
            "text": "The role of the physiotherapist in relation to oxygen therapy includes: \u2022 Assessment of oxygenation prior to, during and following treatment \u2022 Ensuring the patient is receiving oxygen as prescribed",
            "cite_spans": [],
            "ref_spans": [],
            "section": "CONTROLLED OXYGEN THERAPY AND COPD"
        },
        {
            "text": "\u2022 Informing medical staff of increasing oxygen requirements \u2022 Humidifi cation of FiO 2 >30% (or lower if secretions are tenacious).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Calls to the medical unit"
        },
        {
            "text": "Some patients with COPD are classifi ed as oxygen sensitive and have a chronically raised PaCO 2 . They rely on a low PaO 2 to stimulate breathing, rather than an altered pH. This is called hypoxic drive. If too much oxygen is given, their stimulus to breathe (low PaO 2 ) is removed and the patient stops breathing, resulting in type II respiratory failure, sometimes called oxygen-induced respiratory acidosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Calls to the medical unit"
        },
        {
            "text": "It is vital that all COPD patients receive controlled oxygen therapy until it is established whether they are oxygen sensitive (through arterial blood gas analysis).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Calls to the medical unit"
        },
        {
            "text": "\u2022 Maintain adequate O 2 levels (saturations \u226590%) without precipitating respiratory acidosis or worsening hypercapnia.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "BEST PRACTICE FOR INITIAL USE OF SUPPLEMENTAL OXYGEN THERAPY IN COPD (NICE 2004)"
        },
        {
            "text": "\u2022 Deliver O 2 via a controlled system such as a Venturi device. If a mask is not tolerated O 2 may be delivered via nasal cannulae.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "BEST PRACTICE FOR INITIAL USE OF SUPPLEMENTAL OXYGEN THERAPY IN COPD (NICE 2004)"
        },
        {
            "text": "\u2022 Until it is established whether a COPD patient is O 2 sensitive, start FiO 2 at 0.28 and increase until PaO 2 is >7.6 kPa, without causing a signifi cant fall in pH.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "BEST PRACTICE FOR INITIAL USE OF SUPPLEMENTAL OXYGEN THERAPY IN COPD (NICE 2004)"
        },
        {
            "text": "\u2022 The COPD patient with respiratory acidosis, despite optimal medical management and controlled oxygen therapy, will require NIV or IPPV.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "BEST PRACTICE FOR INITIAL USE OF SUPPLEMENTAL OXYGEN THERAPY IN COPD (NICE 2004)"
        },
        {
            "text": "\u2022 If the COPD patient is not O 2 sensitive, increase FiO 2 until saturations are \u226590%.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "BEST PRACTICE FOR INITIAL USE OF SUPPLEMENTAL OXYGEN THERAPY IN COPD (NICE 2004)"
        },
        {
            "text": "(Refer to Chapter 9.) \u2022 Only consider NIV following optimal medical management and controlled O 2 therapy. \u2022 COPD patients are at risk of pneumothorax with positive pressure ventilation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MANAGEMENT OF THE COPD PATIENT WITH RESPIRATORY ACIDOSIS REQUIRING NIV (BRITISH THORACIC SOCIETY STANDARDS OF CARE COMMITTEE 2002)"
        },
        {
            "text": "\u2022 Use controlled O 2 therapy when removing from NIV.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MANAGEMENT OF THE COPD PATIENT WITH RESPIRATORY ACIDOSIS REQUIRING NIV (BRITISH THORACIC SOCIETY STANDARDS OF CARE COMMITTEE 2002)"
        },
        {
            "text": "Physiotherapy can play an important role in establishing the cause of frequent admissions in some patients and in helping to prevent such admissions (Table  12 .1).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 149,
                    "end": 159,
                    "text": "(Table  12",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "CAUSES OF READMISSION IN COPD"
        },
        {
            "text": "It is important to establish the ceiling of treatment agreed by the patient, their family and their medical team. IPPV may be deemed futile, and the fully informed Calls to the medical unit patient may decide that NIV is not in their best interest; treatment may consist solely of medications and physiotherapy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "CARE OF THE PATIENT WITH END-STAGE COPD"
        },
        {
            "text": "Assess the patient and formulate your plan and goals in line with what the patient wishes to achieve. There may be some disparity between what you perceive as optimal treatment and what the patient consents to. Some patients may wish to limit treatment to symptom control while others may feel that any intervention will worsen shortness of breath, outweighing any benefi ts gained, and thus decline what physiotherapy has to offer. These patients, who have had years of coping with unpleasant and disabling symptoms and have often had multiple inpatient admissions, are able to make truly informed choices.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "CARE OF THE PATIENT WITH END-STAGE COPD"
        },
        {
            "text": "Patients with end-stage COPD, together with their families and carers, should have access to the full range of services offered by the multidisciplinary palliative care teams, including admission to hospices. Opioids, benzodiazepines, tricyclic antidepressants and oxygen therapy may be used for the palliation of breathlessness in patients unresponsive to other medical treatments. In the terminal stages of the disease, antisecretory agents may be useful.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "CARE OF THE PATIENT WITH END-STAGE COPD"
        },
        {
            "text": "Optimal medical management is essential during acute exacerbation of asthma and may include magnesium infusion, inhaled or nebulized bronchodilators (beta-2 agonists and antimuscarinics), inhaled, nebulized, oral or intravenous corticosteroids, and theophyllines. Antibiotics will be used if there is evidence of infection (\u2191white cell count, neutrophils and CRP, \u00b1 pyrexia) (Table 12 .2). The tiring patient Inspiratory and expiratory polyphonic wheeze or a silent chest on auscultation are signs of deteriorating asthma Beware of 'normal' blood gases.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 375,
                    "end": 384,
                    "text": "(Table 12",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "ACUTE ASTHMA"
        },
        {
            "text": "Initially patients show type I respiratory failure \u00b1 hypocapnia. As they tire, pCO 2 rises, but ABGs may have been taken as pCO 2 is rising through the normal range. Look for signs of CO 2 retention/narcosis (see Chapter 9)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "ACUTE ASTHMA"
        },
        {
            "text": "\u2022 If you suspect the patient is deteriorating, ask for an urgent medical review \u2022 Use positioning to optimize respiratory muscle function and reduce work of breathing \u2022 Only use sputum clearance techniques if you think sputum retention is signifi cant in causing airway obstruction (refer to Chapter 6) \u2022 Avoid tiring patient further. Restrict to short, regular treatments \u2022 Non-invasive or invasive ventilation will be required for patients with type 2 respiratory failure (refer to Chapter 9) \u2022 ! NB: Check for pneumothorax before applying non-invasive ventilation (refer to CXR and auscultation sections) Calls to the medical unit PANCREATITIS Pancreatitis can be acute (one-off occurrence), chronic where it persists even after the cause has been removed, or hereditary. Causes include gallstones, excessive alcohol consumption, hypertriglyceridaemia, viral infection, trauma, vasculitis or pregnancy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "ACUTE ASTHMA"
        },
        {
            "text": "The aim of physiotherapy is to identify and treat the cause of hypoxaemia (Table 12. 3).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 74,
                    "end": 84,
                    "text": "(Table 12.",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "ACUTE ASTHMA"
        },
        {
            "text": "Renal failure is characterized by raised urea and creatinine levels. Electrolytes may also become deranged (Tables 12.4, 12.5 and 12.6).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TREATMENT OF THE RENAL PATIENT"
        },
        {
            "text": "Oesophageal varices are extremely dilated submucosal veins in the oesophagus. They are a consequence of portal hypertension as seen in liver cirrhosis. They are very likely to bleed and are diagnosed via endoscopy (Table 12 .7).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 214,
                    "end": 223,
                    "text": "(Table 12",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "OESOPHAGEAL VARICES"
        },
        {
            "text": "Interstitial lung disease (ILD) refers to a group of lung diseases characterized by infl ammation which often leads to pulmonary fi brosis. Fibrosis destroys the alveoli, interstitium and capillary network of the affected areas of lung resulting in a restrictive disorder (Table 12 .8). ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 272,
                    "end": 281,
                    "text": "(Table 12",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "INTERSTITIAL LUNG DISEASE"
        },
        {
            "text": "Pneumonia results from an infl ammation of the alveolar space, usually due to invasion by bacteria, viruses or fungi, or as a result of chemical or physical injury. In bacterial and fungal infection, alveoli fi ll with protein-rich fl uid and debris from white blood cells. Sputum production also increases (Table 12 .9). Interstitial pneumonia is characterized by patchy or diffuse infl ammation of the interstitium (the area between the alveoli). The alveoli do not contain signifi cant exudate. \u2022 CPAP is often required to maintain oxygenation \u2022 If type II respiratory failure develops, NIV or invasive ventilation will be required, if appropriate NB: Higher pressures will be required to ventilate 'stiff lungs' so \u2191risk of pneumothorax",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 307,
                    "end": 316,
                    "text": "(Table 12",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "PNEUMONIA"
        },
        {
            "text": "\u2022 Monitor SpO 2 closely during treatment \u2022 Always ensure adequate O 2 delivery when moving the fi brotic patient. An \u2191FiO 2 will probably be required \u2022 Dips in SpO 2 and breathlessness on exertion will resolve with rest and O 2 therapy. Be patient. It may take several minutes",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Calls to the medical unit"
        },
        {
            "text": "Adult cystic fi brosis (CF) patients will have their own independent airway clearance regime. It may comprise of PD \u00b1 self-percussion and ACBT, PEP mask, Flutter device or the Acapella. You do not need to be an expert in all these techniques, but during infective exacerbation you need to assess the effectiveness of the normal regime, and assist with sputum clearance if necessary. Patients may benefi t from PD and manual techniques performed by the physiotherapist. It is advisable to do one or two lung areas with each treatment. Treatment may need to be further modifi ed in the patient with dyspnoea, e.g. modifi ed PD, \u2191emphasis on breathing control (Association of Chartered Physiotherapists in Cystic Fibrosis 2002) (Table  12 .10). ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 725,
                    "end": 735,
                    "text": "(Table  12",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "CYSTIC FIBROSIS (ADULT)"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "include TB, pertussis, measles, aspiration of a foreign body or severe bacterial pneumonia",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Signs and symptoms include chronic purulent sputum production (sometimes several cupfuls a day), regular and often persistent respiratory tract infections, chronic cough, disturbed sleep, fatigue and fi nger clubbing. Bronchiectatic patients, like CF patients, usually have their own airway clearance regime. It may comprise of PD \u00b1 self-percussion and ACBT, PEP mask, Flutter device or the Acapella (see CF section above). In acute infective exacerbation they may require assistance to achieve effective sputum clearance. Common issues include type I respiratory failure, haemoptysis and infection control",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "References Association of Chartered Physiotherapists in Cystic Fibrosis (2002) Clinical guidelines for the physiotherapy management of cystic fi brosis",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care",
            "authors": [],
            "year": 2002,
            "venue": "Thorax",
            "volume": "57",
            "issn": "",
            "pages": "192--211",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Respiratory physiology: the essentials",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "West",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Pulmonary pathophysiology: the essentials",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "West",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "1 Common causes of readmission in the COPD patient",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "2 Common issues in the treatment of patients with acute asthma",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "3 Common issues in the management of the medical patient with pancreatitisCommon issues/complications Advice PainSevere upper abdominal pain radiating to the back causing \u2193TV and atelectasis Opiates may reduce respiratory drive Lobar or lung collapse is common as a consequence of upper abdominal pain NB: \u2193BS may be due to pleural effusion,",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "May be diffi cult to gain informed consent. Treat in patient's best interest Patients may be tissue hypoxic with normal SaO 2 \u2022 May contribute to breathlessness \u00d8Immune response/\u00d8WCC \u2022 \u2191risk of opportunistic infection \u2022 Use reverse barrier methods in line with hospital protocol",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "6 Causes of cardiovascular instability in the patient with renal failure Do not use postural drainage or positive pressure treatments with these patients",
            "latex": null,
            "type": "table"
        },
        "TABREF5": {
            "text": "8 Common issues when treating patients with pulmonary fibrosis",
            "latex": null,
            "type": "table"
        },
        "TABREF6": {
            "text": "Can cause extreme hypoxaemia and rapid onset of type I and II respiratory failure. Non-productive in early stages\u2022 Patients in type II respiratory failure will require NIV or IPPV \u2022 Further physiotherapy not indicated unless evidence of sputum retention \u2022 You may be asked for an induced sputum specimen for diagnosis of P. jiroveci. This is not an on call procedure Highly contagious and mortality is high Last seen in China in 2003 Primary viral pneumonia and secondary bacterial pneumonia as a consequence of pandemic infl uenza\u2022 Follow your local hospital infection control guidelines for pandemic pneumonia \u2022 Only treat those patients who have evidence of sputum retention. Treat as presents, i.e. bronchopneumonia or lobar pneumonia (see above)",
            "latex": null,
            "type": "table"
        },
        "TABREF7": {
            "text": "Table 12.10 Common issues in the treatment of adult CF patients \u2022 Treat as normal \u2022 Use TEEs and gentle huffi ng only. Minimize coughing \u2022 Discontinue physiotherapy until bleeding settles. Humidify O 2 Type I respiratory failure Hypoxaemic episodes will become more common as disease progresses \u2022 Ensure adequate, humidifi ed O 2 therapy. Heated humidifi cation may be necessary with thick secretions \u2022 Effective sputum clearance will decrease airway obstruction and improve oxygenation. Check SpO 2 pre and post treatment \u2022 Monitor SpO 2 and modify treatment if it causes signifi cant dips, e.g. modify PD positions, limit periods of huffi ng, \u2191emphasis on breathing control, salbutamol nebulizer pre or post treatment Common issues Advice Type II respiratory failure NIV may be used as a bridge to lung or heart/lung transplant. Patients may have domiciliary NIV (for overnight use or more prolonged periods) and are likely to be confi dent with its use \u2022 NIV or IPPV will be required for patients in type II respiratory failure \u2022 Treat patients on NIV with their mask on, removing it to allow expectoration \u2022 A nasal mask may be more suitable for those with copious secretions \u2022 Monitor saturations throughout treatment \u2022 This should not infl uence physiotherapy management \u2022 NB: CF patients have an \u2191risk of pneumothorax with positive pressure techniques (See Chapters 5 and 19) Infection control \u2022 Always treat patients with MRSA, Pseudomonas aeruginosa or Burkholderia cepacia last if possible \u2022 Ensure strict hand hygiene and follow local hospital guidelines for infection control Osteoporosis CF patients often have poor uptake of vitamin D which can lead to osteoporosis \u2022 Use caution with manual techniques \u2022 Ensure adequate pain relief prior to treatment if necessary Liver disease This is common in the later stages of CF Ascites will impinge on the diaphragm causing volume loss Liver disease may cause portal hypertension leading to oesophageal varices \u2022 Position patient to allow free movement of the diaphragm (see Chapter 7) \u2022 These patients will not tolerate headdown tilts \u2022 Treatment with the Acapella, Flutter device or PEP mask may be more appropriate \u2022 See previous section on oesophageal varices Terminal stages of CF Not all patients want, or are suitable for, transplant. This is an extremely distressing time for both the patient and their family. Patients should have access to bereavement counsellors and the palliative care team who will manage their symptoms \u2022 Treat for comfort only, at the patient's request",
            "latex": null,
            "type": "table"
        },
        "TABREF8": {
            "text": "",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}